Olympics: High-risk people must get priority over athletes for vaccine – Wiebe

Reuters 01/10/2021

Canada’s Olympic wrestling champion Erica Wiebe has said frontline workers and vulnerable people should be prioritised over Olympic athletes for the novel coronavirus vaccine. Senior Olympics official Dick Pound said on Friday athletes should be given priority…

Oxford and AstraZeneca resume coronavirus vaccine trial

AP 09/13/2020

LONDON — Oxford University announced Saturday it was resuming a trial for a coronavirus vaccine it is developing with pharmaceutical company AstraZeneca, a move that comes days after the study was suspended following a reported side-effect in…

China’s CNBG, Sinovac find more countries to test coronavirus vaccines

Reuters 09/06/2020

BEIJING– China National Biotec Group (CNBG) and Sinovac Biotech Ltd said on Saturday four more countries have agreed to run late-stage clinical tests of their coronavirus vaccine candidates, as China steps up its efforts in the global…

Russia vaccine ‘passes early trial test’

AFP 09/05/2020

LONDON — Early tests of a Russian coronavirus vaccine showed encouraging results when details were published Friday, but experts said the trials were too small to prove safety and effectiveness. Russia announced last month that its vaccine, named…

Companies test antibody drugs to treat, prevent COVID-19

Associated Press 08/12/2020

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to…

Oxford starts human trials for virus vaccine

04/24/2020

LONDON—Oxford University is launching a human trial of a potential coronavirus vaccine, with the daunting aim of making a successful jab available to the public later this year. Of the more than 100 research projects around the…

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.